Key clinical point: Patients with relapsed or refractory acute myeloid leukemia may be more likely to respond when selinexor is added to standard chemotherapy.
Major finding: The overall response rate was 50% for patients receiving cytarabine, idarubicin, and selinexor.
Study details: A phase 2 trial involving 44 patients with relapsed or refractory acute myeloid leukemia.
Disclosures: The study was funded by Karyopharm Therapeutics. Dr. Fielder reported financial disclosures related to Amgen, Pfizer, Jazz Pharmaceuticals, and other companies.
Fiedler W et al. EHA Congress, Abstract S880.